News

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6 th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA.

05/01/2025

Sonnet Releases Virtual Investor "What This Means" Segment

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010

04/16/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Sonnet BioTherapeutics Holdings, Inc. (SONN) a buy, sell, or hold?

Sonnet BioTherapeutics Holdings, Inc. (SONN) can sell. Click on Rating Page for detail.

What is Sonnet BioTherapeutics Holdings, Inc.'s stock price?

The price of Sonnet BioTherapeutics Holdings, Inc. (SONN) is 4.94 and it was updated on 2025-07-11 13:00:26.

Is Sonnet BioTherapeutics Holdings, Inc. (SONN) overvalued or undervalued?

Currently Sonnet BioTherapeutics Holdings, Inc. (SONN) is in undervalued.

News

From:

To:

News
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® ) Fri, Apr. 04, 2025
Sonnet Announces Release of Corporate Update Video PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a corporate update video. Access the video here. Tue, Apr. 01, 2025
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief Executive Officer of the Company, and the promotion of Stephen McAndrew, Ph.D., the Company's current Chief Business Officer, to President and Chief Business Officer of the Company. The Board intends to launch a CEO search. Tue, Apr. 01, 2025
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas SON-1010 is being studied as a combination therapy with trabectedin (Yondelis ® ), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (PFS) Wed, Mar. 26, 2025
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein Company advancing development of its modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR ) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) thus making IL-18 BPR more effective in vitro Wed, Mar. 19, 2025

SEC Filings

SEC Filings
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/02/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/02/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/13/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/04/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/01/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/26/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/19/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/26/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 02/21/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/19/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/13/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 02/13/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 01/31/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 01/30/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/28/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 01/22/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/21/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 01/21/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - POS AM SEC Filings 01/13/2025
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 12/23/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/17/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 12/17/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/10/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B5 SEC Filings 12/10/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/09/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/05/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/04/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-8 SEC Filings 11/26/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/08/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B4 SEC Filings 11/07/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 11/06/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/06/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 11/04/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 10/28/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/17/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/09/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/30/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/18/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/12/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/09/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/30/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 08/19/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - ARS SEC Filings 08/19/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/19/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/14/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/14/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14A SEC Filings 08/09/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/09/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/24/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 07/15/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 07/05/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/20/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/14/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/13/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/22/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/20/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 05/16/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 05/15/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/14/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/14/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 05/03/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/03/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/11/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/06/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/14/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 02/14/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/01/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/29/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 01/05/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 01/02/2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/27/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 12/22/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/15/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/14/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 12/14/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 11/17/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 11/06/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 10/27/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B4 SEC Filings 10/26/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 10/25/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 10/19/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 10/04/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 09/28/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 09/19/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/19/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 09/07/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/01/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/31/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 08/22/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/22/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-8 SEC Filings 08/21/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/14/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/14/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 08/10/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B4 SEC Filings 08/09/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 08/07/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 08/07/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - ARS SEC Filings 08/07/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 07/28/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14A SEC Filings 07/28/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/21/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 07/17/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 07/17/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 07/07/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 06/30/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/30/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B5 SEC Filings 06/29/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 06/22/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/15/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 06/14/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 06/12/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 06/09/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/31/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 05/26/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/18/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 05/17/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/15/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/10/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/10/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 05/02/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/18/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/24/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 03/16/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/10/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 02/17/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/13/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 02/13/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 02/10/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B4 SEC Filings 02/09/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 02/08/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - FWP SEC Filings 02/07/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 02/06/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 01/30/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 01/19/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/19/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/09/2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/22/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/15/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 12/15/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/09/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B5 SEC Filings 11/09/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/02/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/01/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/31/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/17/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/04/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 10/04/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/29/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/21/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 09/19/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 09/19/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/19/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B4 SEC Filings 09/19/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/16/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 09/14/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 09/02/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 08/31/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 08/30/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 08/25/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/25/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 08/19/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14A SEC Filings 08/15/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/15/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B5 SEC Filings 08/15/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/15/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/23/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 06/03/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/03/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 06/02/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-8 SEC Filings 05/10/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/10/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/10/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 04/13/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 04/12/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 04/12/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 04/11/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 04/11/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/11/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/08/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/08/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14A SEC Filings 03/29/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/16/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/08/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 02/08/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 02/03/2022
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/17/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 12/17/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 12/16/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/07/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/31/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/25/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/24/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B4 SEC Filings 08/23/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 08/20/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 08/20/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 08/19/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/19/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 08/16/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 08/16/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/16/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/16/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 08/03/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 07/28/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 07/22/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/15/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 06/14/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/14/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/09/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/08/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 06/07/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 06/04/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/28/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 05/25/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/21/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/20/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-8 SEC Filings 05/17/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - POS AM SEC Filings 05/17/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/17/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/17/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/14/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 05/03/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/03/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/01/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/01/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 04/01/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/30/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 03/10/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 02/16/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/16/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 02/16/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/05/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B5 SEC Filings 02/05/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 01/26/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 01/22/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 01/21/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 01/21/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 01/19/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 01/15/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 01/12/2021
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 12/30/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 12/29/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 12/23/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 12/21/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 12/17/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/17/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 12/17/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/14/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/14/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/04/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 07/16/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 07/16/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 07/15/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3/A SEC Filings 07/13/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 07/13/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 07/10/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/09/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/02/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3/A SEC Filings 06/26/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 06/26/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 06/26/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/12/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 06/05/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4/A SEC Filings 06/05/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 05/26/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 05/20/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-8 SEC Filings 05/20/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/18/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/18/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-Q - Quarterly Report SEC Filings 05/15/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 05/06/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 04/22/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 04/22/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 04/21/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/20/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 04/10/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 04/08/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 04/07/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 04/03/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/03/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/03/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 04/03/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 04/02/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 03/31/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 03/31/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 03/30/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/27/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/26/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 03/24/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 03/24/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/19/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 425 SEC Filings 03/19/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 03/19/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/09/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 03/03/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/03/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 425 SEC Filings 03/03/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/18/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 425 SEC Filings 02/18/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3/A SEC Filings 02/14/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 02/13/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 02/12/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 02/11/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 02/10/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 02/10/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-4/A SEC Filings 02/07/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/07/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 425 SEC Filings 02/07/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/13/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 425 SEC Filings 01/13/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 01/06/2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/27/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 12/10/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/10/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D SEC Filings 12/02/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 12/02/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-4 SEC Filings 11/27/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 11/21/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 11/21/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 11/19/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 11/19/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/14/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/14/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/12/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 425 SEC Filings 11/12/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/16/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 425 SEC Filings 10/16/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/11/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 425 SEC Filings 10/11/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/11/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 09/03/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/26/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/23/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/19/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/19/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/14/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/14/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/31/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 07/23/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 07/17/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 07/09/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/02/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/02/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 07/02/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/27/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/25/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 06/25/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/20/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 06/12/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 06/12/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 06/07/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/04/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/29/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 05/28/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - FWP SEC Filings 05/28/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 05/23/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/23/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4/A SEC Filings 05/22/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/20/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/15/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/15/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/15/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/14/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/06/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 04/30/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 04/15/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 04/10/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4/A SEC Filings 04/08/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/01/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 04/01/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/25/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/08/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 01/08/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/04/2019
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/31/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/20/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 12/20/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/17/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/10/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 11/30/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 11/28/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/23/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 11/16/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/14/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/13/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/08/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/28/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/12/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 09/06/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 08/30/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3/A SEC Filings 08/28/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/23/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3/A SEC Filings 08/16/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/16/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/13/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/13/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3/A SEC Filings 08/08/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 08/07/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 07/13/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 07/10/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/18/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 05/16/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/15/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/14/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/11/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 05/08/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/08/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B5 SEC Filings 05/08/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 04/30/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/26/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/03/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 03/30/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/28/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/20/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/06/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 02/13/2018
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 12/22/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 12/19/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/19/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 12/13/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/04/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 12/01/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/13/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/13/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 10/30/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3/A SEC Filings 10/24/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 10/24/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/13/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B5 SEC Filings 10/13/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/27/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 09/13/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/07/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 09/05/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 09/05/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 09/05/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 08/30/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/30/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/17/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/14/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/14/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 08/09/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/09/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D SEC Filings 06/30/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 25-NSE SEC Filings 06/16/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/15/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/12/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/06/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/02/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/25/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 05/19/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 05/19/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/18/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/18/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/15/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/15/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 05/11/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/05/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 04/19/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 04/13/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRER14A SEC Filings 04/12/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 04/12/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 04/10/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/04/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14A SEC Filings 04/03/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/03/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 03/31/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/28/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 03/20/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/15/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - POS AM SEC Filings 03/10/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/15/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 01/25/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/17/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 01/17/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/13/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 01/13/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - FWP SEC Filings 01/04/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - FWP SEC Filings 01/03/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 01/03/2017
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/30/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 12/30/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/30/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/28/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4/A SEC Filings 12/22/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/22/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/21/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/20/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 12/16/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/16/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B2 SEC Filings 12/15/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 12/14/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 12/12/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 12/09/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 12/08/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 12/05/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 12/05/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 11/29/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 11/28/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 11/18/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 11/16/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 11/14/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/10/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/09/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 10/28/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/28/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 10/06/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 10/06/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/30/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/28/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/23/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/16/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/15/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/07/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/07/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/23/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/18/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/16/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/11/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/11/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 08/01/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/20/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/12/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/07/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/15/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/08/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/23/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/19/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/16/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 04/26/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/21/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/01/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-K - Current report SEC Filings 03/31/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 03/31/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/11/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/23/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 02/11/2016
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 12/09/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 12/09/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3/A SEC Filings 12/07/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/17/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/16/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/19/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 10/14/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/14/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/05/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/28/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/25/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/21/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/16/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/10/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B5 SEC Filings 09/08/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - FWP SEC Filings 09/03/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/03/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/02/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - FWP SEC Filings 08/26/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/25/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/21/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/20/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/18/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/17/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/14/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/13/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 08/06/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 08/06/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/05/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/03/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/03/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 08/03/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/30/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/20/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/06/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/23/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B5 SEC Filings 06/23/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 06/10/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 06/05/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/04/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3/A SEC Filings 06/03/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 06/03/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/01/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 06/01/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/21/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/20/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-Q - Quarterly Report SEC Filings 05/15/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 05/14/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/30/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 04/30/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 04/27/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 04/15/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 04/06/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - POS AM SEC Filings 04/02/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-K - Current report SEC Filings 04/01/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/01/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/31/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/20/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 03/18/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/18/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/16/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 03/16/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/12/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 03/10/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/05/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/26/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 02/20/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 02/18/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/18/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 02/18/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 02/17/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 02/17/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 02/13/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 02/12/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 02/05/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 02/03/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/20/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 01/16/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 01/14/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 01/09/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/08/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/06/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 01/05/2015
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 12/11/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 11/24/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/14/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/14/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 10/16/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/02/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 09/24/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 09/17/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/10/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 09/05/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 09/03/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 08/26/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14A SEC Filings 08/21/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/19/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/15/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/14/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/03/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/30/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/15/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/15/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 04/18/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/08/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 04/04/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/04/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/01/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 03/31/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 02/10/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 02/10/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/06/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-8 SEC Filings 02/04/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 02/04/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 01/23/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 01/23/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 01/21/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3/A SEC Filings 01/17/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 01/17/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/15/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14A SEC Filings 01/08/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/02/2014
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-3 SEC Filings 12/31/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/19/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/12/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/05/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/04/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/02/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 11/20/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-Q - Quarterly Report SEC Filings 11/15/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/15/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/15/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/13/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 11/08/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/07/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/05/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/24/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 10/22/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 10/21/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 10/21/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/21/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 10/15/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/10/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 10/08/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 10/08/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/01/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 09/23/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/14/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 08/13/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/12/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/12/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/05/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEFA14A SEC Filings 06/19/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 06/19/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 06/04/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B4 SEC Filings 06/04/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 05/31/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - POS AM SEC Filings 05/20/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 05/20/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/15/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/14/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 04/23/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - POS AM SEC Filings 04/18/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 04/18/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/15/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/05/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 04/03/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-K - Current report SEC Filings 04/02/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 04/02/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/22/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 03/06/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 03/04/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 02/14/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - POS AM SEC Filings 02/07/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 02/04/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 01/24/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/22/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/16/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 01/14/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 01/02/2013
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/31/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 12/31/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 12/28/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 12/28/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/21/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 12/21/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/19/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 12/19/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/17/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 12/17/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 12/04/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 12/04/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-Q - Quarterly Report SEC Filings 11/15/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 11/05/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 11/02/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 10/26/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 10/24/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 10/24/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/24/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 10/18/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 10/12/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 09/24/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/20/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 09/18/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/18/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/14/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/10/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/23/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/13/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/13/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/02/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 25-NSE SEC Filings 08/02/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/17/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 07/17/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 07/16/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 07/16/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 07/12/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/12/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/27/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 06/21/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/21/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B4 SEC Filings 06/21/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 06/20/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CERTNAS SEC Filings 06/20/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 06/19/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/15/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 06/07/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-A12B SEC Filings 06/07/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 06/05/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 05/30/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/24/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 05/21/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/15/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/14/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 05/07/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 04/24/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 04/12/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14A SEC Filings 04/11/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 04/06/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-K - Current report SEC Filings 03/30/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 02/23/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 02/22/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - AW SEC Filings 02/22/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 02/03/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 02/03/2012
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 12/28/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 12/08/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 12/02/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - D SEC Filings 11/30/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/25/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/14/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 11/10/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/15/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/19/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B3 SEC Filings 08/19/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/18/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/15/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/27/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/22/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - EFFECT SEC Filings 07/15/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 424B4 SEC Filings 07/14/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 07/13/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 07/13/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 07/07/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/07/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 07/06/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 07/06/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 07/06/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/29/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/28/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 06/27/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 06/27/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 06/23/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/21/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1/A SEC Filings 06/13/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/12/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 04/06/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/01/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-K - Current report SEC Filings 03/31/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/29/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 03/28/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/18/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14A SEC Filings 02/10/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 02/02/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14A SEC Filings 01/24/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 01/24/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - S-1 SEC Filings 01/06/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G/A SEC Filings 01/05/2011
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 12/07/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14C SEC Filings 11/24/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/12/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 10/28/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 10/01/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/16/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/12/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/06/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/28/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/14/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/07/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/18/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/14/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/29/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/27/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/14/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 03/31/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 03/24/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 03/15/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 03/15/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 03/10/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 5 SEC Filings 03/09/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 03/09/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 02/25/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 02/23/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 02/22/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 01/28/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 01/21/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 01/21/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 01/19/2010
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 12/15/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/07/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 11/24/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 11/23/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 11/20/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 11/13/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/13/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 11/09/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 11/04/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 10/05/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/22/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 09/09/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 09/09/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 09/04/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K/A - Current report SEC Filings 09/04/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 09/01/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 08/21/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/20/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/11/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/13/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - CORRESP SEC Filings 07/10/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - UPLOAD SEC Filings 06/25/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/02/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/21/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/05/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/27/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 03/06/2009
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/14/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 5 SEC Filings 10/10/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 40-17G SEC Filings 10/06/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 08/21/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 08/15/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/14/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/11/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13G SEC Filings 08/07/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/06/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/28/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - N-54C SEC Filings 07/21/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/18/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 2-E SEC Filings 07/18/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/14/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 07/08/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 07/03/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/03/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/02/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 07/01/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - DEF 14C SEC Filings 06/20/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRER14C SEC Filings 06/18/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 2-E/A SEC Filings 06/10/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/03/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - PRE 14C SEC Filings 05/23/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/23/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 05/09/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/09/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 05/07/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/07/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/05/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 05/02/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 04/23/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/23/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 04/07/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 04/07/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 03/31/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 1-E SEC Filings 03/27/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 03/14/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/13/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 02/19/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 2-E SEC Filings 02/19/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 02/08/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 02/08/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 02/05/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 02/05/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D/A SEC Filings 01/14/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 01/14/2008
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/14/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 11/09/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 10/01/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/27/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/13/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 06/07/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/14/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 1-E SEC Filings 04/12/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 04/02/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 01/16/2007
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 12/12/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/13/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 10/24/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q/A - Quarterly Report SEC Filings 10/23/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 10/20/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 10/10/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 2-E SEC Filings 09/25/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K/A - Current report SEC Filings 09/20/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 09/13/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 2-E SEC Filings 08/10/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/10/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 08/08/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 07/07/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 06/13/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 05/12/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - SC 13D SEC Filings 05/10/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-K - Current report SEC Filings 03/30/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 4 SEC Filings 01/18/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3/A SEC Filings 01/18/2006
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 11/09/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 3 SEC Filings 10/27/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10-Q - Quarterly Report SEC Filings 08/15/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 1-E SEC Filings 07/28/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 1-E SEC Filings 06/03/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/02/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - N-54A SEC Filings 06/01/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 06/01/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 05/31/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 05/10/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10KSB SEC Filings 03/31/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 8-K - Current report SEC Filings 03/23/2005
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-Q - Quarterly Report SEC Filings 11/16/2004
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 11/16/2004
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 08/23/2004
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-Q - Quarterly Report SEC Filings 08/17/2004
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 04/30/2004
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10SB12G/A SEC Filings 04/23/2004
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10KSB/A SEC Filings 04/23/2004
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10KSB SEC Filings 04/14/2004
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-K - Current report SEC Filings 03/31/2004
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 12/29/2003
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 08/14/2003
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 08/13/2003
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10KSB SEC Filings 04/10/2003
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-K - Current report SEC Filings 03/31/2003
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 11/05/2002
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 08/06/2002
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 05/10/2002
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10KSB SEC Filings 03/18/2002
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 10/25/2001
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 08/06/2001
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 05/03/2001
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10KSB SEC Filings 04/16/2001
Sonnet BioTherapeutics Holdings, Inc. (SONN) - NT 10-K - Current report SEC Filings 03/30/2001
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 11/03/2000
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 08/14/2000
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10QSB SEC Filings 04/26/2000
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10SB12G/A SEC Filings 03/07/2000
Sonnet BioTherapeutics Holdings, Inc. (SONN) - 10SB12G SEC Filings 02/15/2000

Press Releases

StockPrice Release
Sonnet chief medical officer, richard kenney, m.d., to present at the 6th annual cytokine-based drug development summit 05/01/2025
Sonnet releases virtual investor "what this means" segment 04/16/2025
Sonnet's son-1010 demonstrates a strong safety profile in combination with atezolizumab for treatment of platinum-resistant ovarian cancer, including a partial response at the highest dose 04/04/2025
Sonnet announces release of corporate update video 04/01/2025
Sonnet announces the passing of founder and ceo pankaj mohan, ph.d. 04/01/2025
Sonnet biotherapeutics successfully completes first safety review of son-1010 in combination with trabectedin in certain sarcomas 03/26/2025
Sonnet biotherapeutics receives notice of allowance for u.s. patent covering composition of matter of specific amino acid substitutions of its il-18 binding protein resistant variant protein 03/19/2025
Sonnet biotherapeutics holdings, inc. participates in the virtual investor “top 5 for ‘25” on-demand conference 03/11/2025
Sonnet biotherapeutics presents compilation of data highlighting the potential of son-1010 as a monotherapy or a combination therapy to improve the treatment of solid tumors 02/26/2025
Sonnet biotherapeutics announces that its proprietary antibody drug conjugate (adc) platform is available for drug discovery partnerships with potential for producing multiple pipeline drug candidates 02/19/2025
Sonnet biotherapeutics selected for poster presentation at the 2025 aacr io conference 02/18/2025
Sonnet biotherapeutics appoints stephen mcandrew, ph.d. as chief business officer 02/13/2025
Sonnet biotherapeutics provides fiscal year 2025 first quarter business and earnings update 02/13/2025
Sonnet biotherapeutics further expands global intellectual property portfolio with issuance of eu patent for fhab® platform technology 01/28/2025
Sonnet biotherapeutics to present at live! with webull corporate connect: healthcare investment webinar 01/22/2025
Sonnet biotherapeutics expands phase 1 sb101 trial to evaluate combination of son-1010 with trabectedin in certain sarcomas 01/21/2025
Sonnet biotherapeutics announces release of the next ceo corner segment 12/23/2024
Sonnet biotherapeutics reports fiscal year 2024 financial results and provides corporate update 12/17/2024
Sonnet biotherapeutics announces $3.9 million registered direct offering and concurrent private placement priced at-the-market under nasdaq rules 12/09/2024
Sonnet biotherapeutics announces topline safety data following successful completion of son-1010 monotherapy dose escalation in phase 1 sb101 trial 12/09/2024
Sonnet biotherapeutics announces publication detailing the discovery and development of son-1010, an albumin-binding il-12 fusion protein, demonstrating its mechanism of action 12/04/2024
Sonnet biotherapeutics releases virtual investor ‘”what this means” segment 11/12/2024
Sonnet biotherapeutics announces pricing of $5.0 million underwritten public offering priced at-the-market under nasdaq rules 11/06/2024
Sonnet biotherapeutics announces issuance of u.s. patent covering a variant il-18 incorporated into two novel immunotherapeutic drug candidates 11/06/2024
Sonnet biotherapeutics inc. regains compliance with nasdaq 10/17/2024
Sonnet biotherapeutics inc. enters into licensing agreement with alkem laboratories limited to develop and commercialize son-080 for diabetic peripheral neuropathy (dpn) in india 10/09/2024
Sonnet biotherapeutics to receive non-dilutive funding through new jersey tax certificate transfer and australia r&d tax incentive programs 10/04/2024
Sonnet biotherapeutics announces launch of ceo corner platform 09/30/2024
Sonnet biotherapeutics announces 1-for-8 reverse stock split 09/25/2024
Sonnet biotherapeutics completes enrollment in phase 1 study of son-1010 (il12-fhab) as a monotherapy (sb101) for the treatment of solid tumors 09/18/2024
Sonnet biotherapeutics to participate in the virtual investor closing bell series 09/04/2024
Sonnet biotherapeutics enters into clinical collaboration agreement to commence investigator-initiated and funded phase 1/2a study of son-1210 in combination with chemotherapy for the treatment of pancreatic cancer 08/19/2024
Sonnet biotherapeutics reports third quarter fiscal year 2024 financial results and provides corporate update 08/14/2024
Sonnet biotherapeutics (nasdaq:sonn) participates in virtual investor "what this means" segment hosted by jtc team 07/24/2024
Sonnet biotherapeutics reports encouraging data from phase 1b/2a clinical trial of son-080 in chemotherapy-induced peripheral neuropathy (cipn) that support advancement into phase 2 study 07/24/2024
Sonnet biotherapeutics to present sb221 as a trial in progress at the asco 2024 annual meeting 05/28/2024
Sonnet biotherapeutics announces updated clinical data for son-1010 as monotherapy or combined with an anti-pd-l1, along with an increase in the dose-escalation target 05/20/2024
Sonnet biotherapeutics provides fiscal year 2024 second quarter and year-to-date business and earnings update 05/14/2024
Sonnet biotherapeutics announces participation in the ef hutton annual global conference 05/06/2024
Sonnet biotherapeutics announces participation in the ef hutton annual global conference 05/03/2024
Sonnet biotherapeutics to present preclinical data on son-080 for chemotherapy-induced peripheral neuropathy (cipn) at the aacr 2024 annual meeting 03/19/2024
Sonnet biotherapeutics announces early safety data from the company's phase 1b/2a clinical trial of son-080 in chemotherapy-induced peripheral neuropathy (cipn) met the study's initial pre-specified objective 03/11/2024
Sonnet biotherapeutics announces a publication demonstrating safety and tolerability of son-1010 in healthy volunteers 02/29/2024
Sonnet biotherapeutics provides fiscal year 2024 first quarter business and earnings update 02/14/2024
Sonnet biotherapeutics announces publication demonstrating suitability of son-1210, the first albumin-binding bifunctional il-12/il-15 fusion protein, for solid tumor immunotherapy 12/21/2023
Sonnet biotherapeutics provides fiscal year 2023 business and financial update 12/14/2023
Sonnet biotherapeutics provides fiscal year 2023 business overview 10/31/2023
Sonnet biotherapeutics announces pricing of $4.55 million underwritten public offering 10/25/2023
Sonnet biotherapeutics announces abstract accepted for presentation by a key opinion leader at the 2023 connective tissue oncology society (ctos) annual meeting 10/17/2023
Sonnet biotherapeutics announces results of biodistribution studies demonstrating solid tumor targeting using the fhab technology 09/20/2023
Sonnet biotherapeutics regains nasdaq minimum bid price compliance 09/19/2023
Sonnet biotherapeutics announces 1-for-22 reverse stock split 08/31/2023
Sonnet biotherapeutics announces fda acceptance of the company's ind for the sb221 clinical trial of son-1010 combined with atezolizumab in the us 08/16/2023
Sonnet biotherapeutics provides fiscal year 2023 third quarter business and earnings update 08/14/2023
Sonnet biotherapeutics to present at the 2023 btig virtual biotechnology conference 07/31/2023
Sonnet biotherapeutics announces $2.25 million registered direct offering and concurrent private placement 06/28/2023
Sonnet biotherapeutics announces presentations at the 2023 cytokine-based drug development summit and provides preliminary update on the son-080 study in chemotherapy-induced peripheral neuropathy 06/23/2023
Sonnet biotherapeutics announces regulatory approval for initiation of a clinical trial of son-1010 combined with atezolizumab 06/20/2023
Sonnet biotherapeutics provides fiscal year 2023 second quarter and year-to-date business and earnings update 05/10/2023
Sonnet biotherapeutics announces updated clinical data for son-1010 at the 2023 american association for cancer research (aacr) annual meeting 04/18/2023
Sonnet biotherapeutics announces webcast to discuss clinical data from the sb101 study with son-1010 being presented at the aacr 2023 annual meeting 04/17/2023
Sonnet biotherapeutics to present clinical data from the sb101 study with son-1010 at the aacr 2023 annual meeting 03/14/2023
Sonnet biotherapeutics provides fiscal year 2023 first quarter business and earnings update 02/13/2023
Sonnet biotherapeutics announces pricing of $15.0 million underwritten public offering 02/08/2023
Sonnet biotherapeutics announces successful completion of two ind-enabling toxicology studies with son-1210 in non-human primates 02/01/2023
Sonnet biotherapeutics announces pharmacokinetic and pharmacodynamic data in a phase 1 dose-escalation trial of son-1010 01/19/2023
Sonnet biotherapeutics announces a collaboration with roche for the clinical evaluation of son-1010 with atezolizumab in ovarian cancer 01/09/2023
Sonnet biotherapeutics provides fiscal year 2022 business and financial update 12/15/2022
Sonnet biotherapeutics announces interim data in two phase 1 dose-escalation trials of son-1010 11/02/2022
Sonnet biotherapeutics announces webcast to discuss interim data from the company's phase 1 dose-escalation trials of son-1010 on november 2, 2022 11/01/2022
Sonnet biotherapeutics announces an agreement with janssen for the evaluation of three sonnet product candidates 10/31/2022
Sonnet biotherapeutics regains compliance with nasdaq minimum bid price requirement 10/04/2022
Sonnet biotherapeutics announces progress in two phase 1 dose-escalation trials of son-1010 09/21/2022
Sonnet biotherapeutics announces 1-for-14 reverse stock split 09/16/2022
Sonnet biotherapeutics announces clinical trial of son-080 in patients with persistent chemotherapy-induced peripheral neuropathy 07/22/2022
Sonnet biotherapeutics announces clinical trial of son-1010 in healthy volunteers 07/21/2022
Sonnet biotherapeutics announces positive results from a preclinical combination study of son-1010 with anti-pd1 checkpoint inhibition 06/09/2022
Sonnet biotherapeutics announces adjournment of annual meeting due to lack of quorum 06/02/2022
Sonnet biotherapeutics provides fiscal year 2022 second quarter business and earnings update 05/10/2022
Sonnet biotherapeutics announces first patient dosed in phase 1 clinical trial of son-1010 for advanced solid tumors 04/13/2022
Sonnet biotherapeutics announces preclinical data supporting its bispecific interleukin candidates at the american association for cancer research (aacr) 2022 annual meeting 04/08/2022
Sonnet biotherapeutics announces fda clearance of its ind for son-1010 for the treatment of advanced solid tumors 03/16/2022
Sonnet biotherapeutics announces abstract accepted for presentation in a poster session at the aacr 2022 annual meeting 02/09/2022
Sonnet biotherapeutics provides fiscal year 2022 first quarter business and earnings update 02/08/2022
Sonnet biotherapeutics provides fiscal year 2021 business and financial update 12/17/2021
Sonnet announces successful completion of the discovery phase for its next preclinical pipeline candidate (son-1410) 08/30/2021
Sonnet biotherapeutics announces pricing of $30 million underwritten public offering 08/19/2021
Sonnet biotherapeutics provides fiscal year 2021 third quarter business and earnings update 08/16/2021
Sonnet biotherapeutics announces change in date of annual meeting 06/14/2021
Sonnet biotherapeutics announces issuance of u.s. patent for platform technology 06/08/2021
Sonnet biotherapeutics provides fiscal year 2021 second quarter business and earnings update 05/17/2021
Sonnet biotherapeutics completes successful glp repeat dose toxicology study of il12-fhab (son-1010) in non-human primates (nhp) 05/10/2021
Sonnet biotherapeutics completes licensing agreement with new life therapeutics 05/03/2021
Sonnet biotherapeutics provides 2021 business update 03/29/2021
Sonnet biotherapeutics appoints richard kenney as chief medical officer and manuel dafonseca as head of clinical operations 03/22/2021
Sonnet biotherapeutics files prospectus relates solely to resale by selling stockholders of up to 5.5 million shares of common stock 07/16/2020
Sonnet biotherapeutics holdings successfully completes merger with private sonnet biotherapeutics 05/18/2020
Sonnet biotherapeutics holdings files prospectus relates solely to resale by selling stockholders of up to 29.5 million shares 04/22/2020
Chanticleer holdings announces 1-for-26 reverse stock split 03/31/2020
Chanticleer holdings - selling shareholders may offer, resell up to 2.8 mln shares of common stock - sec filing 03/24/2020
Chanticleer holdings says record date for spin-off of its restaurant business has now been established as march 26 03/16/2020
Oz rey reports stake in chanticleer holdings 12/02/2019
Chanticleer holdings reports q3 loss per share $0.39 11/14/2019
Chanticleer holdings announces merger agreement with sonnet biotherapeutics 10/10/2019

More Headlines

News
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference On-demand video webcast now available here 03/11/2025
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ® ) provides enhanced targeting to the tumor microenvironment (TME) and prolonged retention in the tumor PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the presentation of a compilation of data at the 2025 American Association for Cancer Research (AACR) IO Conference. 02/26/2025
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) 02/19/2025
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its abstract has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference taking place on February 23-26, 2025 at the JW Marriott in Los Angeles, CA. 02/18/2025
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. 02/13/2025
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR) 02/13/2025
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins 01/28/2025
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar Live webcast on Wednesday, January 29 th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that Pankaj Mohan, Ph.D., Chief Executive Officer of Sonnet will present at LIVE! 01/22/2025
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis ® ) with the potential to improve trabectedin's therapeutic window in soft-tissue sarcoma patients 01/21/2025
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company's website . 12/23/2024
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) 12/17/2024
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered into a definitive agreement with institutional investors for the purchase and sale of an aggregate of 1,085,325 shares of its common stock (or common stock equivalents in lieu thereof) (the “Registered Direct Shares”) and warrants to purchase up to an aggregate of 1,085,325 shares of common stock (the “Registered Direct Warrants”), in a registered direct offering. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold in the registered direct offering together with one common warrant at a combined offering price of $2.23, priced at-the-market under the rules of the Nasdaq Stock Market. The Registered Direct Warrants will have an exercise price of $2.10 per share, are immediately exercisable and will expire five years from the date of issuance. The Company has also entered into a definitive agreement with an existing investor, in a concurrent private placement, for the purchase and sale of an aggregate of 673,000 shares of its common stock (or common stock equivalents in lieu thereof) (the “PIPE Shares”) and warrants to purchase up to an aggregate of 673,000 shares of common stock (the “PIPE Warrants”). Each share of common stock (or pre-funded warrant in lieu thereof) is being sold in the private placement offering together with one common warrant at a combined offering price of $2.23, priced at-the-market under the rules of the Nasdaq Stock Market. The PIPE Warrants will have an exercise price of $2.10 per share, are immediately exercisable and will expire five years from the date of issuance. 12/09/2024
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level 12/09/2024
Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action Pankaj Mohan, CEO of Sonnet discusses what this publication means in a Virtual Investor “What This Means” segment; access here 12/04/2024
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company's recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and SON-1411 11/12/2024
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced the pricing of an underwritten public offering of 1,111,111 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and common warrants to purchase up to an aggregate of 2,222,222 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one common warrant at a combined offering price of $4.50, priced at-the-market under the rules of the Nasdaq Stock Market, for total gross proceeds of approximately $5.0 million, before underwriting discounts and commissions and offering expenses payable by Sonnet. Each common warrant is exercisable for two shares of common stock at an exercise price of $4.50 per share for a period of five years from the date of issuance. The offering is expected to close on or about November 7, 2024, subject to the satisfaction or waiver of customary closing conditions. 11/06/2024
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP) 11/06/2024
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it received notice on October 16, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company regained compliance with the bid price requirement in Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued listing on the Nasdaq Capital Market. 10/17/2024
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India Sonnet to receive $1.0 million in upfront payment and up to an additional $1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India market 10/09/2024
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs PRINCETON, NJ, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced it has received preliminary approval for a tax credit from the New Jersey Technology Business Tax Certificate Transfer Program administered by the New Jersey Economic Development Authority (NJEDA). Sonnet received approval of its application to sell up to $8,143,144 of its New Jersey State net operating losses (NOLs) and $62,810 of its New Jersey State research and development (R&D) tax credits for proceeds of up to $0.795 million through the New Jersey Technology Business Tax Certificate Transfer Program, subject to execution of such sale. Sonnet also expects to receive a $0.7 million net cash refund from the R&D Tax Incentive Program in Australia. 10/04/2024
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress 09/30/2024
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-8 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on Monday, September 30, 2024. 09/25/2024
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold' tumors ‘hot' Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the completion of enrollment and initiation of dosing in its Phase 1 SB101 clinical trial of SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors. 09/18/2024
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it will participate in the Virtual Investor Closing Bell Series on Monday, September 9, 2024, at 4:00 PM ET. 09/04/2024
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy 08/19/2024
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) 08/14/2024
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team Watch the "What This Means" segment here FRENCHTOWN, NJ / ACCESSWIRE / July 24, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Sonnet BioTherapeutics, Inc. (Nasdaq:SONN), a clinical-stage company developing targeted immunotherapeutic drugs. As part of the "What This Means" segment, Pankaj Mohan, PhD, Founder and Chief Executive Officer, Richard Kenney, M.D. 07/24/2024
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study PRINCETON, N.J., July 24, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced encouraging data from the Phase 1b portion of its Phase 1b/2a clinical trial evaluating SON-080 for the treatment of CIPN (the “SB211 study”). The SB211 study is a double-blind, randomized, controlled trial of SON-080 conducted at two sites in Australia in patients with persistent CIPN using a new proprietary version of recombinant human Interleukin-6 (rhIL-6) that builds upon previous work with atexakin alfa. The goal of the Phase 1b portion of the SB211 study was to confirm safety and tolerability before continued development in Phase 2. As previously announced in March 2024, a data and safety monitoring board reviewed the unblinded safety and tolerability of SON-080 in the first nine patients and concluded that the symptoms were tolerable in the initial patients and the study could proceed to Phase 2. Additionally, the Company participated in a Virtual Investor “What This Means” segment to further discuss the Phase 1b data and highlight what this means for its development program moving forward. Click here to access the segment. 07/24/2024
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the SB221 study of SON-1010 (recombinant human Interleukin-12 linked to Sonnet's fully-human albumin binding domain or IL12-FHAB) dosed in combination with atezolizumab (Tecentriq®) will be presented as a ‘Trial in Progress' poster at ASCO 2024. Study SB221 (NCT05756907) is a Phase 1b/2a multicenter, dose-escalation, and proof-of-concept clinical study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered SC, either alone or in combination with a fixed dose of atezolizumab given IV. The work will be presented in a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2024, to be held May 31 to June 4 in Chicago, Illinois. 05/28/2024
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of SON-1010 with atezolizumab (Tecentriq®) without dose-limiting toxicity at any dose levelCytokine data reveals about 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNγ responses, with no evidence of cytokine release syndrome at any doseClinical benefit was seen at four months post-initiation of dosing in 35% of evaluable patients (8/23) with advanced solid tumors PRINCETON, NJ / ACCESSWIRE / May 20, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010 dosing has been formally reviewed in both of the current Phase 1 clinical trials and the Company is now increasing the target dose of SON-1010 during dose escalation. SON-1010 is a proprietary version of recombinant human interleukin-12 (rhIL-12), configured using Sonnet's Fully Human Albumin Binding (FHAB®) platform, which extends the half-life and activity of the IL-12 component due to binding native albumin in the serum and targets the tumor microenvironment (TME) by strongly binding gp60 and Secreted Protein Acidic and Rich in Cysteine (SPARC). SB101 is a Phase 1 multiple-ascending dose (MAD) trial in adult patients with advanced solid tumors (NCT05352750) that commenced in Q2 2022 and is currently enrolling the sixth dose cohort. SB221 is a Phase 1b/2a dose-escalation and proof-of-concept study of the combination of SON-1010 with atezolizumab (in collaboration with Genentech, a member of the Roche Group), in a study focused on platinum-resistant ovarian cancer (PROC) (NCT05756907) that started in Q4 2023, now enrolling the fourth dose cohort. In addition, SON-1010 was studied in SB102, which was a Phase 1 single-ascending dose (SAD) trial in healthy volunteers (NCT05408572) that started in Q3 2022; the results were recently published (Kenney, et al, Frontiers in Immunology, 2024).Safety in both of the active cancer trials has been reviewed by their respective Safety Review Committees at each step during dose escalation. Both trials use a ‘desensitizing' first dose to take advantage of the known tachyphylaxis with rhIL-12, which minimizes toxicity and allows higher maintenance doses. No dose-limiting toxicities or related serious adverse events have occurred to date. The safety and toxicity profile that has developed is typical for a Phase 1 oncology trial, with the majority of adverse events (AEs) being reported as mild. All have been transient, with no evidence of cytokine release syndrome. Of the 25 cancer patients dosed to date and evaluable for follow-up at this latest cutoff, 15 (60%) had stable disease at their first follow-up scan, 8 of whom were progressing at study entry. At four months follow-up, 8 of 23 evaluable patients remained stable at the second CT scan, suggesting clinical benefit of SON-1010 in 35% of the patients."We have now dosed 18 cancer patients at increasing SON-1010 drug levels in the SB101 study, completed dosing in 31 healthy volunteers in SB102, and are rapidly filling the dose-escalation cohorts with 12 subjects enrolled in the first four cohorts of the SB221 combination study," said Richard Kenney, M.D., Sonnet's Chief Medical Officer. "The overall safety and toxicity profile for SON-1010, primarily including local reactions, headache, myalgia, and fatigue, mimics the published experience with rhIL-12, which prompted us to raise the target dose to enhance potential efficacy. The SB102 study allowed us to generate clean data for the pharmacokinetic (PK) and pharmacodynamic (PD) analyses, enabling simulation of the effect of multiple doses with the help of a continual reassessment model of PK and PD. This modeling suggests target-mediated drug disposition (TMDD), which supports the mechanism of the FHAB being directed to tumor tissue. The combination of SON-1010 with atezolizumab may benefit from the ability of IL-12 to turn ‘cold' tumors ‘hot', which upregulates the amount of PD-L1 in the TME."One patient with progressive endometrial sarcoma receiving SON-1010 monotherapy in SB101 had stable disease (SD) for almost 2 years before progressing - her ascites had resolved and tumors had shrunk at one point but she never reached a partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) rules. Cytokine analysis following each dose in that study revealed controlled and prolonged induction of interferon gamma (IFNγ) that peaked at 24 to 48 hours and returned to baseline within 2 to 4 weeks. A small increase in IL-10 was observed with each dose as expected in response to IFNγ. There was either a minimal or no signal for IL-1β, IL-6, IL-8, and TNFα, and there was no indication of any potential for cytokine release syndrome (CRS) at these doses. One patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have received 8 and 10 cycles, respectively, and are continuing on the study. The stable AE profiles despite dose escalation led us to reevaluate the target dose, so the Company has added groups in both studies to evaluate 1200 ng/kg SON-1010 as a maintenance dose (the molar equivalent of 800 ng/kg rhIL-12). Finally, Part 2 of the SB221 combination study has been trimmed to remove the monotherapy arm."The findings to date in these two trials represent significant progress for the SON-1010 molecule", said Robert Wenham, M.D., Chair, Department of GYN Oncology at Moffitt Cancer Center and the Lead Principal Investigator for SB221. "Multiple strategies to present IL-12 safely have been tried over the past two decades with little evidence of improved tolerability in humans, yet the preclinical models continue to suggest that induction of IFNγ in the TME can activate an effective anti-tumor response. This also results in the local induction of PD-L1. Adding a cohort to increase the target MTD of SON-1010, an extended PK molecule that is concentrated in the TME, is the right approach at this stage. This will provide a chance to study the safety of SON-1010 monotherapy in SB101, and then in combination with atezolizumab in SB221, along with the clinical effect of the combination on PROC in a limited set of subjects in the expansion cohort later this year. Defining the best dose for SON-1010 is required to allow a direct randomized comparison of the strategy with the standard of care therapy in Part 2.""We are very pleased with the data we are seeing at these higher dose levels of SON-1010, with safety and tolerability being well within expected levels, as well as displaying SON-1010 extended PK/PD, tumor targeting, and clinical activity during treatment," said Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. "Research on rhIL-12 in humans has been hindered by toxicity for decades. We believe that the IL-12 component in SON-1010 is presented in a way that is safer, due to the longer half-life, and it is concentrated in the tumor, due to the recurrent binding of the FHAB-associated albumin to SPARC in the TME. It is important to note that many of these patients have been fighting their cancers for a very long time and have exhausted all approved treatment regimens available to them, so seeing tumor shrinkage at any dose is both difficult to achieve and encouraging for future results. We are excited to continue testing the impact of SON-1010 in combination with atezolizumab at these higher dose levels in patients with PROC, who represent a significant unmet medical need, and we expect to have a further update early next year."About SON-1010SON-1010 is a candidate immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3. This was selected to bind both at normal pH, as well as at the acidic pH typically found in the TME. The FHAB technology targets tumor and lymphatic tissue, providing a mechanism for dose sparing and an opportunity to improve the safety and efficacy profile of not only IL-12, but a variety of potent immunomodulators that can be added using the platform. Interleukin-12 can orchestrate a robust immune response to many cancers and pathogens. Given the types of proteins induced in the TME, such as the Secreted Protein and Rich in Cysteine (SPARC) and glycoprotein 60 (GP60), several types of cancer such as non-small cell lung cancer, melanoma, head and neck cancer, sarcoma, and some gynecological cancers are particularly relevant for this approach. SON-1010 is designed to deliver IL-12 to local tumor tissue, turning ‘cold' tumors ‘hot' by stimulating IFNγ, which activates innate and adaptive immune cell responses and increases the production of Programed Death Ligand 1 (PD-L1) on tumor cells.About the SB101 Phase 1 TrialThis first-in-human study is primarily designed to evaluate the safety of multiple ascending doses of SON-1010 in cancer patients and will be conducted at several sites across the United States. While the optimal dose is unknown at this stage, the potential to target tumors, the extended PK mechanism and our preclinical data suggest the therapeutic dose may be lower compared to native human IL-12. The study, utilizing a standard 3+3 oncology design in at least five cohorts, should establish the MTD and the recommended Phase 2 dose (RP2D) using monthly subcutaneous injections of SON-1010. The primary endpoint explores the safety and tolerability of SON-1010, with key secondary endpoints intended to measure pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity. This study will form the basis for potential combinations with other types of immunotherapies and the future development of bispecific candidates using the FHAB platform.About the SB221 Phase 1b/2a TrialSB221 is a global Phase 1b/2a multicenter, dose-escalation and randomized proof-of-concept study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered subcutaneously (SC), either alone or in combination with atezolizumab given intravenously (IV). The study is designed in Part 1 to rapidly establish the maximum tolerated dose (MTD) of the combination in patients with advanced solid tumors at the lower dose levels. The focus shifts to PROC at higher dose levels using small dose-escalation groups with expansion of the dataset at the recommended Phase 2 dose (RP2D). This would be followed in Part 2 by an assessment in patients with PROC of the potential for improved efficacy of the combination versus the standard of care. Both companies look forward to this collaboration as an opportunity to improve outcomes for patients with ovarian cancer.About Sonnet BioTherapeutics Holdings, Inc.Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company's clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or the Company's financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.Sonnet BioTherapeutics Investor ContactJack YauchSolebury Strategic Communications862-754-1024jyauch@soleburystrat.comSOURCE: Sonnet BioTherapeutics Holdings, Inc. 05/20/2024
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteers Announced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients with chemotherapy-induced peripheral neuropathy (CIPN) Received $4.3 million in net proceeds from the sale of net operating losses through the New Jersey Technology Business Tax Certificate Transfer Program Presented preclinical data and information on the clinical trial design from the study of SON-080 in CIPN in a poster session at the American Association for Cancer Research (AACR) Annual Meeting PRINCETON, NJ / ACCESSWIRE / May 14, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months and six months ended March 31, 2024 and provided a business update. "We are very excited about the progress we made during the first calendar quarter of this year with the SON-1010 and SON-080 programs, where the foundations for the compounds' safety profiles were further strengthened. 05/14/2024
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference PRINCETON, NJ / ACCESSWIRE / May 6, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The Plaza Hotel in New York. Pankaj Mohan, Ph.D. 05/06/2024
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The Plaza Hotel in New York. Pankaj Mohan, Ph.D. 05/03/2024
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (recombinant human Interleukin-6 or rhIL-6) in CIPN will be presented in a poster session at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 5-10, in San Diego, California. Presentation details: Title: Low dose interleukin-6 (SON-080) for neuropathies: Toxicology and clinical plans Session Title: Pharmacology and Pharmacogenetics Presentation Type: Poster Session Date and Time: Wednesday April 10, 2024, 9:00 AM - 12:30 PM Abstract Number: 7181 Location: Poster Section 24 Poster Board Number: 22 About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. 03/19/2024
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability of SON-080 was consistent with data from previous IL-6 candidates, meeting the Phase 1b safety objective Sonnet will leverage this safety data to support initiation of a Phase 2 clinical trial in Diabetic Peripheral Neuropathy (DPN), a much larger indication, after a potential partnership is put in place PRINCETON, NJ / ACCESSWIRE / March 11, 2024 / Sonnet BioTherapeutics Holdings, Inc. ("Sonnet" or the "Company"), (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the first Phase 1b/2a clinical trial of SON-080 was cleared to proceed to Phase 2 after review by the independent DSMB. This study (SB211, NCT05435742) is being conducted at two sites in Australia in patients with persistent CIPN using a new proprietary version of recombinant human Interleukin-6 (rhIL-6), which required confirmation of safety before continued development in Phase 2. 03/11/2024
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology. SON-1010, Sonnet's lead proprietary monofunctional compound, combines the company's fully-human albumin-binding (FHAB) construct with single-chain interleukin 12 (IL‑12). 02/29/2024
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offering Extensive preclinical data on SON-1210 published in Frontiers in Immunology Received approval and executed agreement to sell New Jersey state net operating losses (NOLs) for expected net proceeds of $4.3 million Enrollment of the Phase 1b portion of the SON-080 trial in chemotherapy-induced peripheral neuropathy (CIPN) has completed PRINCETON, NJ / ACCESSWIRE / February 14, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapeutic drugs for cancer, announced today its financial results for the three months ended December 31, 2023 and provided a business update. "This last quarter set the stage for an exciting year across Sonnet's pipeline, highlighted by the progress of the combination study of SON-1010 and atezolizumab in platinum-resistant ovarian cancer (PROC), where we continue to expect safety data during the first half of 2024. 02/14/2024
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy PRINCETON, NJ / ACCESSWIRE / December 21, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of extensive preclinical data on SON-1210 in Frontiers in Immunology. SON-1210, Sonnet's lead proprietary bifunctional compound, combines the company's FHAB construct with a novel single-chain IL-12 and fully human Interleukin 15 (IL-15). 12/21/2023
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs focused on oncology, announced today its financial results for the fiscal year ended September 30th, 2023 and provided a business update. "Sonnet has had a very productive year, exemplified by important achievements across our pipeline. 12/14/2023
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview Following the recent completion of a $4.55 million financing, Sonnet projects cash runway into the calendar year third quarter of 2024 The company is focused on its business development initiatives and anticipates being able to provide an update in the next few quarters The company continues to advance its therapeutic pipeline with the initiation of the SB221 study with SON-1010 in platinum-resistant ovarian cancer (PROC); early safety data from the SON-080 study in CIPN are expected before the end of 2023 PRINCETON, NJ / ACCESSWIRE / October 31, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, provided a fiscal year 2023 business overview. "As has been our objective since the company's founding, we are committed to innovating next generation cancer treatments of significant potential utility for patients and caregivers, alike," commented Pankaj Mohan, Ph.D. 10/31/2023
Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today? Sonnet BioTherapeutics (NASDAQ: SONN ) stock is falling on Wednesday after the biotechnology company revealed details of a public share offering. That public stock offering has Sonnet BioTherapeutics selling 2,843,750 shares of SONN stock at a price of $1.60 each. 10/25/2023
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering PRINCETON, NJ / ACCESSWIRE / October 25, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("we," "us," "our," "Sonnet" or the "Company"), a clinical-stage company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 2,843,750 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 5,687,500 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with two investor warrants at a combined offering price of $1.60, for total gross proceeds of approximately $4.55 million, before underwriting discounts and commissions and offering expenses payable by Sonnet. 10/25/2023
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting PRINCETON, NJ / ACCESSWIRE / October 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that previously announced interim data from the SB101 clinical trial of the company's proprietary Fully Human AlbuminBinding (FHAB) candidate, SON-1010 (IL12- FHAB), will be presented by Dr. Sant Chawla, a key opinion leader in the field of sarcoma research, at the upcoming Connective Tissue Oncology Society Annual Meeting 2023, which will be held November 1‑4, in Dublin, Ireland. "We are excited to be part of Sonnet's first-in-human use of SON-1010 in the cancer setting that is being studied in the SB101 trial," said Sant Chawla, MD, Principal Investigator and Director of the Sarcoma Center in Santa Monica, California. 10/17/2023
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology Two independent radiolabeling studies showed a 2.5- to 4.7-fold increase in tumor tissue with mIL12-FHAB, the mouse version of SON‑1010, compared with mIL-12 alone Accumulation was observed in tumors compared to normal mice, and was expectedly transient in liver and kidney The model shows that the FHAB technology provides tumor targeting and retention, as well as extended half-life, that importantly complements results from the human clinical studies PRINCETON, NJ / ACCESSWIRE / September 20, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced data from two radiolabeling studies that validate the tumor targeting attributes associated with albumin binding by the FHAB technology. Sonnet performed two independent in vivo proof-of-concept (POC) studies to show the biodistribution of interleukin-FHAB molecules to the tumor microenvironment (TME), using labs with expertise in radiolabeling biologics and in vivo biodistribution analysis. 09/20/2023
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance PRINCETON, NJ / ACCESSWIRE / September 19, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market indicating that Sonnet has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with the Rule, the Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on September 15, 2023. 09/19/2023
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product. 08/25/2023
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer. 08/17/2023
Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US An IND was required to conduct the SB221 study of platinum-resistant ovarian cancer (PROC) with the combination of Sonnet's SON-1010 and Roche's atezolizumab (Tecentriq ® ) in the US As part of the overall design of the program, the clinical trial was initiated at several sites in Australia after HREC regulatory approval and TGA notification The IND acceptance by FDA allows for a global clinical effort, with the possibility for more rapid recruitment through the addition of US trial sites PRINCETON, NJ / ACCESSWIRE / August 16, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the IND for SB221 (NCT05756907), the Phase 1b/2a clinical trial of SON-1010(IL12-FHAB) in combination with Roche's anti-PD-L1 checkpoint inhibitor, atezolizumab, has been accepted, and the study can begin in the US for the treatment of PROC. The trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (MTD) of SON-1010 with a fixed dose of atezolizumab. 08/16/2023
Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update Combination study of SON-1010 with Roche's atezolizumab (Tecentriq®) has been initiated in Australia First SON-1010 Phase 1 study has been completed and comparison of the human pharmacokinetic data supports targeting of tumor tissue Early safety data from the SON-080 trial in CIPN is expected after the study's Data Safety Monitoring Board (DSMB) convenes, prior to calendar year end Collaboration with Janssen,where in vitro and in vivo efficacy of SON-1010, SON-1210, and SON-1410 are being evaluated in combination with certain Janssen cell therapy assets, remains ongoing PRINCETON, NJ / ACCESSWIRE / August 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30, 2023 and provided a business update. "Sonnet continues to successfully forge ahead with our pipeline development," said Pankaj Mohan, Ph.D. 08/14/2023
Why Is Sonnet BioTherapeutics (SONN) Stock Down 5% Today? Sonnet BioTherapeutics (NASDAQ: SONN ) stock is taking a beating on Monday after the company announced a public stock offering. Investors will note that this public stock offering comes from selling stockholders and not directly from Sonnet BioTherapeutics. 07/31/2023
Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference PRINCETON, NJ / ACCESSWIRE / July 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that Pankaj Mohan, PhD, Founder and Chief Executive Officer, Jay Cross, Chief Financial Officer, and Richard Kenney, MD, Chief Medical Officer, will be presenting a corporate overview at the BTIG Virtual Biotechnology Conference, held August 7-8, 2023. Sonnet BioTherapeutics Fireside Chat Details: 2023 BTIG Virtual Biotechnology ConferenceDate: Monday, August 7, 2023Presentation Time: 12:00 pm ET Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the offering, the closing of the offering, the amount and anticipated use of proceeds from the offering, the timing of an IND submission, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. 07/31/2023
Best Penny Stocks to Buy Under $1? 10 To Watch Now Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1. 06/22/2023
Best Penny Stocks to Buy Under $1? 7 To Watch Now Typically, we refer to stocks trading for less than $5 per share, as penny stocks. However, for this article, we're focusing specifically on penny stocks under $1. 06/16/2023
Best Penny Stocks to Buy Under $1? 4 To Watch Now Ever find yourself daydreaming about striking it rich in the stock market? Well, buckle up, because we're about to dive headfirst into the world of penny stocks under $1. 06/15/2023
4 Penny Stocks To Watch Under $5 With Big News This Week Everyone is looking for an edge to find penny stocks to buy before the masses. The difficult part of this is that many of these cheap stocks lack liquidity. 05/26/2023
3 Hot Penny Stocks To Watch Under $1, Time To Buy? Penny stocks under $1 to watch this week. The post 3 Hot Penny Stocks To Watch Under $1, Time To Buy? 05/18/2023
Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting PRINCETON, NJ / ACCESSWIRE / April 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share data from its SB101 clinical study with SON-1010 in oncology patients (NCT05352750) on Tuesday, April 18, 2023 at 5:00 pm ET. Webcast presenters will include: Richard Kenney, M.D. 04/17/2023
Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting PRINCETON, NJ / ACCESSWIRE / March 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from the company-sponsored SB101 multiple-dose clinical trial (NCT05352750) of SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors will be presented in a poster session at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, in Orlando, Florida. Presentation details: Title: Clinical development of a novel form of interleukin-12 with extended pharmacokinetics Session Title: Phase I and First-in-Human Clinical Trials in Progress Presentation Type: Poster Session Date and Time: Tuesday April 18, 2023, 1:30 PM - 5:00 PM Abstract Number: CT245 Location: Poster Section 46 About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific, bifunctional action. 03/14/2023
5 Hot Penny Stocks To Watch This Week With Big News Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 01/09/2023
Best Penny Stocks To Buy? 5 To Watch For November 2022 Penny stocks to watch this week. The post Best Penny Stocks To Buy? 11/07/2022
Using Reddit to Find Penny Stocks to Buy? Use These Tips Here's how to find penny stocks on Reddit right now The post Using Reddit to Find Penny Stocks to Buy? Use These Tips appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 11/02/2022
Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company's Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022 PRINCETON, NJ / ACCESSWIRE / November 1, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share initial clinical data from its SB101 clinical study with SON-1010 in oncology patients (NCT05352750) and its SB102 clinical study with SON-1010 in healthy volunteers (NCT05408572) on Wednesday, November 2, 2022 at 8:30 am ET. Webcast presenters will include:Richard Kenney, M.D. 11/01/2022
How to Take Advantage of Market Volatility With Penny Stocks Are these money making tips part of your penny stocks trading strategy? The post How to Take Advantage of Market Volatility With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 11/01/2022
Why Is Sonnet BioTherapeutics (SONN) Stock Up 100% Today? The award for today's most impressive mover has to go to Sonnet BioTherapeutics (NASDAQ: SONN ). Currently, SONN stock has surged more than 120% on an intraday move that has seen this stock erase more than a month of losses. 10/31/2022
Top Penny Stocks to Buy Now? 3 to Watch in July Check these three penny stocks out for your watchlist right now The post Top Penny Stocks to Buy Now? 3 to Watch in July appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 07/15/2022
Check These Penny Stocks For Your Watchlist This Week Can these penny stocks climb this week? The post Check These Penny Stocks For Your Watchlist This Week appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 07/11/2022
Hot Penny Stocks to Buy in Mid-June 2022? 3 to Watch Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy in Mid-June 2022? 06/09/2022
Trending Penny Stocks to Buy This Month? 3 to Watch in April Can these penny stocks continue to climb this month? The post Trending Penny Stocks to Buy This Month? 04/17/2022
Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now? 04/13/2022
Sonnet Shares Surge As FDA Clears Its First Human Trial For Solid Tumor Candidate The FDA has signed off Sonnet BioTherapeutics Holdings Inc's (NASDAQ: SONN) Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) technology. Sonnet will. 03/16/2022
Trading Penny Stocks? Top Stock Market News for March 16th, 2022 What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for March 16th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 03/16/2022
Sonnet BioTherapeutics (SONN) Stock: Why The Price Fell The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) fell by 4.57% in the most recent trading session. This is why it happened. 02/09/2022
Top Penny Stocks to Buy This Week? 3 You Need to Watch With October off to a great start for penny stocks, which small-caps are you watching? The post Top Penny Stocks to Buy This Week? 10/04/2021
Penny Stocks That Will Explode? Check These 3 Out For Your List Check these three penny stocks out for your September watchlist The post Penny Stocks That Will Explode? Check These 3 Out For Your List appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 09/15/2021
SONN Stock: Why It Significantly Increased Today The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 20% pre-market. This is why it happened. 09/15/2021
Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now? 09/03/2021
See Why Sonnet BioTherapeutics Stock Is Skyrocketing In Premarket Tuesday Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock is soaring during premarket in reaction to the selection of SON-1410 as a development candidate for melanoma and renal cancers. SON-1410 represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the Company's Fully Human Albumin Binding (FHAB) platform. 08/31/2021
SONN Stock: Over 60% Increase Pre-Market Explanation The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 60% pre-market. This is why it happened. 08/31/2021
Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410) SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs Selection of the asset was performed with input from Sonnet's Scientific Advisory Board An IND submission for SON-1410 is anticipated during the second half of 2022 PRINCETON, NJ / ACCESSWIRE / August 30, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has selected a novel development candidate after completing comparative studies in a mouse melanoma model. The candidate represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the company's Fully Human Albumin Binding (FHAB) platform. 08/30/2021
Sonnet BioTherapeutics Stock Slumps After $30M Equity Raise Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) priced the underwritten public offering of 35.3 million shares (including pre-funded warrants) and warrants to purchase up to 35.3 million shares. Each share of common stock (or pre-funded warrant) has a combined price of $0.85, raising approximately $30.0 million gross proceeds. 08/20/2021
Sonnet BioTherapeutics Shares Fall Over 45% Pre-Market: Why It Happened The shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) fell over 45% pre-market. This is why it happened. 08/20/2021
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 35,294,117 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 35,294,117 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of $0.85, for total gross proceeds of approximately $30.0 million, before underwriting discounts and commissions and offering expenses payable by Sonnet. 08/19/2021
Buying Penny Stocks Right Now? 3 to Watch in 2021 Looking to buy penny stocks in 2021? Check these 3 out for your list The post Buying Penny Stocks Right Now? 08/19/2021
SONN Stock: The Social Media Buzz Sending Sonnet Bio Rocketing Today Sonnet BioTherapeutics (SONN) stock is taking off on Thursday and investors can thank retail traders on social media for pumping it higher. The post SONN Stock: The Social Media Buzz Sending Sonnet Bio Rocketing Today appeared first on InvestorPlace. 08/19/2021
Sonnet BioTherapeutics Shares Increase Over 200% Pre-Market: Why It Happened The shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 200% pre-market. This is why it happened. 08/19/2021
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update Expanded F H AB Intellectual Property Portfolio Completed $15.9 million At-The-Market Financing SON-1010 and SON-080 on track for IND submissions by calendar year end PRINCETON, NJ / ACCESSWIRE / August 16, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30th , 2021 and provided a business update. "Throughout the quarter, we've continued to make several advancements towards the clinic with our proprietary Fully Human Albumin Binding (F H AB) pipeline assets, and our partnered product" commented Pankaj Mohan, Ph.D. 08/16/2021
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has changed the date of its upcoming annual meeting of stockholders (the "Annual Meeting") called for the purpose of approving certain proposals, including the election of directors and the ratification of the appointment of Sonnet's independent auditing firm for the fiscal year ended September 30, 2021, from June 24, 2021 to Thursday July 15, 2021 at 9:00 a.m. 06/14/2021
Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 06/08/2021
SONN Stock: Over 6% Increase Pre-Market Explanation The stock price of Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) increased by over 6% pre-market. This is why it happened. 05/10/2021
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP) The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release syndrome. Pharmacokinetic (PK) analysis of serum samples confirmed an enhanced profile of IL12-FHAB over recombinant human IL-12, with a half-life around 40 hours in NHP. 05/10/2021
SONN Stock: From $2.37 To $2.57 (8.44% Increase) Pre-Market Explanation The stock price of Sonnet BioTherapeutics Holdings, Inc. (Nasdaq: SONN) increased from $2.37 to $2.57 (up 8.44%) pre-market. This is why it happened. 05/03/2021
3 Penny Stocks With Huge Potential in May 2021 Penny stocks are back and better than ever; should you watch these 3 in May? The post 3 Penny Stocks With Huge Potential in May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 05/03/2021
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories Upfront and potential milestone payments totaling up to $21 Million with up to 30% royalties on commercial sales NLT to fund Phase 1b/2a clinical trial and submit an IND planned for the second half of 2021 PRINCETON, NJ / ACCESSWIRE / May 3, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has executed a definitive agreement with New Life Therapeutics Pte. Ltd. (NLT ) of Singapore for the license of low-dose Interleukin 6, or IL-6, for the treatment of Diabetic Peripheral Neuropathy (DPN). 05/03/2021
Hot Penny Stocks To Buy on Robinhood? Here's 4 To Watch Top penny stocks on Robinhood? Here's 4 to check out for your May watchlist The post Hot Penny Stocks To Buy on Robinhood? 04/30/2021
Sonnet BioTherapeutics Provides 2021 Business Update PRINCETON, NJ / ACCESSWIRE / March 29, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today a business update on its ongoing programs. "Last year we continued execution across our pipeline, and I am excited to share an update on our ongoing activities," commented Pankaj Mohan, Ph.D. 03/29/2021
Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021. 03/22/2021
2 Falling Knives to Catch Wall Street recommends buying shares of Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) and Sigma Labs Inc. (NASDAQ:SGLB), which you would not expect after these 2 stocks performed so poorly over the prior 52 weeks through Friday, and lost more than 59%. As a result of the sharp decline in the share price, these stocks are known as "falling knives. 12/21/2020

Unlock

SONN Ratings Summary

SONN Quant Ranking